Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aztreonam.

S J Childs, G P Bodey

    Pharmacotherapy
    |July 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Aztreonam, a novel monobactam antibiotic, shows potent activity against Gram-negative bacteria, including resistant strains. Its safety profile and targeted efficacy make it a promising alternative to traditional therapies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Serious complications of vascular catheter-related Staphylococcus aureus bacteremia in cancer patients.

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·1992
    Same author

    Infectious complications of indwelling vascular catheters.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1992
    Same author

    Viral pneumonia in the immunocompromised adult with neoplastic disease: the role of common community respiratory viruses.

    Seminars in respiratory infections·1992
    Same author

    Lack of activity of amphotericin B in systemic murine fusarial infection.

    The Journal of infectious diseases·1992
    Same author

    Evaluation of strategies for central venous catheter replacement.

    Critical care medicine·1992
    Same author

    Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1992
    Same journal

    The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

    Pharmacotherapy·2026
    Same journal

    Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

    Pharmacotherapy·2026
    Same journal

    Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

    Pharmacotherapy·2026
    Same journal

    Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

    Pharmacotherapy·2026
    Same journal

    Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

    Pharmacotherapy·2026
    Same journal

    Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

    Pharmacotherapy·2026
    See all related articles

    Area of Science:

    • Microbiology
    • Pharmacology
    • Infectious Diseases

    Background:

    • Beta-lactam antibiotics are widely used but face resistance due to beta-lactamase enzymes.
    • Emergence of resistant bacterial strains necessitates development of novel antimicrobial agents.
    • Monobactams represent a distinct class of beta-lactam antibiotics with unique properties.

    Purpose of the Study:

    • To introduce aztreonam, a synthetic monobactam antibiotic.
    • To evaluate its spectrum of activity, pharmacokinetic profile, and safety.
    • To assess its potential as an alternative therapeutic agent.

    Main Methods:

    • Review of aztreonam's chemical structure and mechanism of action.
    • Analysis of in vitro susceptibility data against various bacterial pathogens.

    Related Experiment Videos

  • Evaluation of pharmacokinetic and pharmacodynamic properties based on clinical studies.

    • Main Results:

    • Aztreonam is highly resistant to hydrolysis by most plasmid- and chromosomally-mediated beta-lactamases.
    • Exhibits potent activity against Gram-negative organisms, including Enterobacteriaceae, Hemophilus, and Neisseria species.
    • Demonstrates favorable pharmacokinetic profile with good tissue distribution and renal elimination.
    • Well-tolerated with a favorable safety profile, lacking significant hematologic, otic, or renal toxicity.

    Conclusions:

    • Aztreonam is a safe and effective monotherapy for Gram-negative infections, including those caused by beta-lactamase-producing strains.
    • Its unique properties and safety profile position it as a valuable alternative to aminoglycosides.
    • Further clinical evaluation is warranted to establish its role in various treatment settings.